Symberix Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $305K

  • Investors
  • 5

Symberix General Information

Description

Developer of gut microbiome-targeting drugs designed to improve human health. The company's research discovers a way to target enzymes produced by the gut microbiome, which causes chemotherapeutic side effects, enabling patients with the treatment of lower gastrointestinal (GI) diseases as well as mitigate the debilitating lower GI side effects associated with various cancer, pain, and immunosuppressive therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Laboratory Services (Healthcare)
Corporate Office
  • 4819 Emperor Boulevard
  • Suite 400
  • Durham, NC 27703
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Symberix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Grant 10-Jun-2022 $305K 00.000 Completed Generating Revenue
8. Grant 01-Jan-2020 00.000 00.000 Completed Startup
7. Grant 01-May-2019 00000 00.000 Completed Startup
6. Grant 01-Jan-2019 00000 00.000 Completed Startup
5. Grant 01-Jan-2019 00.000 00.000 Completed Startup
4. Grant 01-Apr-2018 00000 00.000 Completed Startup
3. Debt - General 09-Feb-2018 00000 00.000 Completed Startup
2. Grant 06-Aug-2014 $1.47M $3.5M Completed Startup
1. Angel (individual) $3.5M $3.5M Completed Startup
To view Symberix’s complete valuation and funding history, request access »

Symberix Patents

Symberix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220125778-A1 Compounds, compositions, and methods for selectively inhibiting beta-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea Pending 07-Mar-2019 00000000
EP-3934644-A4 Compounds, compositions, and methods for selectively inhibiting beta-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea Pending 07-Mar-2019 00000000 0
EP-3934644-A1 Compounds, compositions, and methods for selectively inhibiting ?-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea Pending 07-Mar-2019 00000000
CA-3128760-A1 Compounds, compositions, and methods for selectively inhibiting .beta.-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea Pending 07-Mar-2019 00000000
EP-3710003-A1 Compounds, compositions, and methods for selectively inhibiting beta- -glucuronidases and alleviating side effects associated with drug treatment induced diarrhea Pending 08-Sep-2017 A61P1/12
To view Symberix’s complete patent history, request access »

Symberix Executive Team (4)

Name Title Board Seat Contact Info
Ward Peterson Ph.D Co-Founder, Chief Executive Officer & Chairman
Matthew Redinbo Ph.D Co-Founder & Chief Scientific Officer
Marilyn Thompson Controller
Gregory Mossinghoff Chief Business Officer
To view Symberix’s complete executive team members history, request access »

Symberix Board Members (1)

Name Representing Role Since
Ward Peterson Ph.D Symberix Co-Founder, Chief Executive Officer & Chairman 000 0000
To view Symberix’s complete board members history, request access »

Symberix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Symberix Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institute of General Medical Sciences Government 000 0000 000000 0
National Center For Advancing Translational Sciences Government 000 0000 000000 0
National Institute of Diabetes and Digestive and Kidney Diseases Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
To view Symberix’s complete investors history, request access »

Symberix FAQs

  • When was Symberix founded?

    Symberix was founded in 2013.

  • Who is the founder of Symberix?

    Ward Peterson Ph.D and Matthew Redinbo Ph.D are the founders of Symberix.

  • Who is the CEO of Symberix?

    Ward Peterson Ph.D is the CEO of Symberix.

  • Where is Symberix headquartered?

    Symberix is headquartered in Durham, NC.

  • What is the size of Symberix?

    Symberix has 4 total employees.

  • What industry is Symberix in?

    Symberix’s primary industry is Drug Discovery.

  • Is Symberix a private or public company?

    Symberix is a Private company.

  • What is Symberix’s current revenue?

    The current revenue for Symberix is 00000.

  • How much funding has Symberix raised over time?

    Symberix has raised $3.75M.

  • Who are Symberix’s investors?

    National Institute of General Medical Sciences, National Center For Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, and National Cancer Institute have invested in Symberix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »